BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21951673)

  • 21. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases.
    Gusterson BA; Warburton MJ; Mitchell D; Ellison M; Neville AM; Rudland PS
    Cancer Res; 1982 Nov; 42(11):4763-70. PubMed ID: 6290045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Squamous cell carcinoma in situ of the breast: a light microscopic and immunohistochemical study of a previously undescribed lesion.
    Hayes MM; Peterse JL; Yavuz E; Vischer GH; Eusebi V
    Am J Surg Pathol; 2007 Sep; 31(9):1414-9. PubMed ID: 17721198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.
    Ballehaninna UK; Chamberlain RS
    J Clin Oncol; 2011 Feb; 29(4):e97-8; author reply e99. PubMed ID: 21172894
    [No Abstract]   [Full Text] [Related]  

  • 25. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
    Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upgrade Rate and Imaging Features of Atypical Apocrine Lesions.
    Chang Sen LQ; Berg WA; Carter GJ
    Breast J; 2017 Sep; 23(5):569-578. PubMed ID: 28333404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apocrine intraductal carcinoma in situ in nevus sebaceus: two case reports.
    Llamas-Velasco M; Requena L; Podda M; Weidenthaler-Barth B; Rütten A
    J Cutan Pathol; 2014 Dec; 41(12):944-9. PubMed ID: 25302933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up.
    Seidman JD; Ashton M; Lefkowitz M
    Cancer; 1996 Jun; 77(12):2529-37. PubMed ID: 8640702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
    Sitterding SM; Wiseman WR; Schiller CL; Luan C; Chen F; Moyano JV; Watkin WG; Wiley EL; Cryns VL; Diaz LK
    Ann Diagn Pathol; 2008 Feb; 12(1):33-40. PubMed ID: 18164413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
    Selim AG; El-Ayat G; Wells CA
    Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
    Bratthauer GL; Saenger JS; Strauss BL
    Histopathology; 2005 Dec; 47(6):611-6. PubMed ID: 16324199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apocrine carcinoma of the breast.
    Gădăleanu V; Galatâr N
    Morphol Embryol (Bucur); 1986; 32(1):33-8. PubMed ID: 3010089
    [No Abstract]   [Full Text] [Related]  

  • 33. Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases.
    Ross DS; Hoda SA
    Am J Surg Pathol; 2011 May; 35(5):750-6. PubMed ID: 21415700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DCIS and LCIS with multinucleated giant cells-a report of 4 cases.
    Coyne JD
    Histopathology; 2007 Apr; 50(5):669-71. PubMed ID: 17394507
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of invasion in breast lesions using antibodies to basement membrane components and myoepithelial cells.
    Raymond WA; Leong AS
    Pathology; 1991 Oct; 23(4):291-7. PubMed ID: 1664512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of HER2 protein examination in ductal carcinoma in situ.
    Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F
    J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
    Shim HS; Jung WH; Kim H; Park K; Cho NH
    APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [S-phase fraction of benign mastopathies and breast carcinomas].
    Kunz J; Winzer KJ
    Zentralbl Chir; 1991; 116(7):483-6. PubMed ID: 1647602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-operative breast pathology: apocrine lesions.
    Wells CA; El-Ayat GA
    J Clin Pathol; 2007 Dec; 60(12):1313-20. PubMed ID: 18042688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.